Peptide therapyThe future of medicine
Peptides are short chains of amino acids that act as signaling molecules in the body. They play crucial roles in regulating a wide range of physiological processes, including metabolism, immune function, and cellular repair.
There is growing public discussion about whether certain peptides may become more accessible in the future. But as of now, the FDA has not formally changed its position.
The peptides most commonly mentioned in these conversations include AOD-9604, BPC-157, DSIP, Epitalon, GHK-Cu, Kisspeptin-10, KPV, MOTS-C, Semax, Selank, TB-500, and Thymosin Alpha-1. Today, they remain in Category 2 and are not currently eligible for routine 503A compounding.
Category 1 and Category 2 are not the same as FDA approval. Category 1 generally refers to substances that are still under FDA review but may be compounded while that review is ongoing. Category 2 refers to substances the FDA has identified as presenting significant safety concerns, meaning they cannot be routinely compounded unless the agency formally changes that status.
At Crimson Health, we take a disciplined, physician-led approach to care with rigorous standards for quality, safety, and compliance. Every treatment plan is individualized and built around what is right for the patient.
As the regulatory landscape evolves, we will continue to monitor developments closely while staying focused on safe, evidence-informed care.
Peptide protocols. Coming soon
Physician-supervised peptide therapies tailored to your biology.
All plans are HSA/FSA eligible · Cancel anytime · No hidden fees
We're committed to your care.
As the regulatory landscape evolves, we remain committed to safe, evidence-informed care. Explore some of our current offerings below.
Explore Offerings